Navigation Links
Cancer signatures uncovered
Date:8/15/2008

A new systematic analysis of the relationship between the neoplastic and developmental transcriptome provides an outline of trends in cancer gene expression. The research, published recently in BioMed Central's open access journal Genome Biology, describes how cancers can be divided into three groups distinguished by disparate developmental signatures.

Isaac S Kohane from Children's Hospital Boston and Harvard University, US, led a team of researchers who performed a comprehensive comparison of genes expressed in early developmental stages of various human tissues and those expressed in different cancers affecting these tissues. He says, "Our study reveals potentially clinically relevant differences in the gene expression of different cancer types and represents a reference framework for interpretation of smaller-scale functional studies".

One of the three described groups of cancers has an early developmental phenotype and expresses genes that are characteristic of stem cells. From a developmental perspective, this group presents very homogeneously. A second, more heterogeneous group tends to be more similar to late development and is characterized by an inflammatory signature. The third is a small group of cancers that present as a transition phenotype between these two extremes and displays both characteristics.

According to Kohane, "This segregation of tumors into three groups with distinct expression patterns is surprising. Clearly, the developmental trajectory provides a meaningful background for capturing large-scale differences in gene expression across diverse conditions".

The study's results will lead towards a better understanding of human disease from a 'macrobiological' approach to analyzing high-throughput data. According to the authors, "Shifting our focus from single sets of genes or processes to the biology of aggregates on the order of the entire transcriptome is likely to be useful in establishing highly robust molecular correlations between seemingly unrelated disease phenotypes".


'/>"/>
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-707-94804
BioMed Central
Source:Eurekalert

Related biology news :

1. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
2. Scientists discover major genetic cause of colorectal cancer
3. Commercialization aim of grant supporting technology that destroys cancer cells
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. Monash researchers uncover cancer survival secrets
6. Researchers find cancer-inhibiting compound under the sea
7. Pre-cancerous condition linked to chronic acid reflux faces several hurdles
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
10. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
11. A new cellular pathway linked to cancer is identified by NYU researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: